Bio-Engine Launches Two New MSC Culture Medium Products: Population Doubling Time Only 15 Hours, Exosome Yield Increased By 2.8-Fold

SHANGHAI, BioEngine Sci-Tech Co, Ltd.  recently announced the official launch of two innovative products dedicated to Mesenchymal Stem Cells (MSCs): the Omni-Expansion MSC Culture Kit and Exo MSC CD Exosome Expression Kit. The two products are engineered to address long-standing industrial bottlenecks in MSC expansion and exosome manufacturing, including insufficient production efficiency, poor batch-to-batch consistency and regulatory compliance challenges. This launch marks Bio-Engine's deeper layout in the Cell and Gene Therapy (CGT) sector by expanding its product portfolio to the stem cell subdivision, delivering comprehensive serum-free culture solutions for global clients.

Bio-Engine is an established player in the CGT industry. Multiple existing culture medium lines from the company have supported numerous partners to advance their cell therapy programs into clinical stages, accumulating solid technical experience spanning lab-scale process development to cGMP-grade large-scale manufacturing. The two newly released MSC-specific kits are technological extensions built upon this mature industrial platform.

 

Four Decades of Cell Cultivation Expertise Underpin Superior Product Performance

 

Bio-Engine's founding team initiated stem cell culture research as early as 1995, ranking among China's earliest pioneers with continuous R&D engagement in this field. Backed by profound technical accumulation, Bio-Engine has built an in-house proprietary medium formulation library and scalable manufacturing system, covering nutritional requirements and growth kinetics of diverse cell lines. The newly unveiled MSC product series represents the industrialized translation of the company's decades-long technical know-how in specialized stem cell cultivation.

 

Omni-Expansion MSC Culture Kit: 15.1 Hours Population Doubling Time at Low Passages, Balanced Cell Quantity and Quality

 

To resolve key industrial pain points during large-scale MSC expansion, including risks of animal-derived contamination, severe batch variation and unstable scale-up performance, Bio-Engine's Omni-Expansion MSC Culture Kit adopts a serum-free, xeno-free, chemically defined formulation with breakthrough advantages as follows:

1. Markedly shortened population doubling time: Only 15.1 hours for low-passage MSCs (

2. Robust long-term passaging capacity: Maintains a population doubling time of 22.7 hours post P10, fully meeting the demands of mass production.

3. Multi-tissue source compatibility: Supports primary isolation, stable subculture and high-density expansion of MSCs derived from umbilical cord, adipose tissue, bone marrow and other tissues.

4. Dual compatibility for 2D and 3D culture: Preserves canonical fibroblastic morphology and trilineage differentiation potential in 2D monolayer culture; delivers an 18.3-fold cell expansion on Day 4 in 3D microcarrier workflows, featuring uniform cell attachment and consistent cell viability.

5. Strict maintenance of MSC immunophenotype: Positive rates of CD105/CD73/CD90 >99%, while positive rates of hematopoietic markers CD45/CD34 <2%.

6. Rigorous quality control specifications: Endotoxin level ≤0.125 EU/mL, validated against dozens of physicochemical, biosafety and functional performance indicators.

 

The kit's low-protein formulation is highly optimized for subsequent exosome production. Early customer feedback confirms: "Superior expansion efficiency compared to alternative commercial media" and "Compatible with both 2D and 3D culture, facilitating seamless process scale-up."

 

Exo MSC CD Exosome Expression Kit: 2.8-Fold Higher Exosome Yield, Greatly Improved Purification Efficiency

 

Targeting core hurdles hindering exosome drug development - low vesicle yield, high impurity loads and pronounced batch-to-batch variability - the Exo MSC CD Exosome Expression Kit is custom-formulated for MSC cultivation during exosome manufacturing stages:

1. Industry-leading exosome yield: Produces exosome titers of 1.6×10¹⁰ particles/mL, representing a 2.1-fold and 2.8-fold increase versus mainstream Brand A (7.8×10⁹ particles/mL) and Brand B (5.7×10⁹ particles/mL), respectively.

2. High particle size homogeneity: Main peak particle diameter at 121.6 nm accounting for 97.1% of total vesicles, consistent with the canonical size range of exosomes (30–150 nm).

3. Validated vesicle morphology and biomarker profiles: Transmission Electron Microscopy (TEM) confirms characteristic cup-shaped biconcave disc ultrastructure; Western Blot analysis detects positive expression of exosome markers TSG101, CD63 and CD9, alongside negative expression of endoplasmic reticulum marker Calnexin, verifying intact vesicle integrity and high purity.

4. Serum-free, chemically defined composition: Eliminates batch-to-batch inconsistency, streamlines downstream purification workflows and elevates total vesicle recovery rates.

5. End-to-end serum-free workflow compatibility: Can be paired with the Omni-Expansion MSC Culture Kit to realize a continuous serum-free process covering MSC primary isolation, serial passaging and exosome harvest.

 

Users may implement a continuous harvesting workflow: After cell attachment, switch culture medium to this kit, collect cell culture supernatant and replenish fresh medium every 48 hours to achieve consistent, high-efficiency exosome production.

 

Expanded CGT Product Portfolio to Accelerate Clinical IND Submission and Commercial-Scale Manufacturing

Bio-Engine has established a complete serum-free medium product line covering immune cells (T cells, NK cells and other effector cells) for CGT applications, with multiple products enabling clients to advance their pipelines into clinical trials. The launch of the new MSC product series extends Bio-Engine's CGT solution ecosystem into stem cell therapeutics, offering end-to-end serum-free culture options spanning immune cells and mesenchymal stem cells, from cell amplification to exosome biomanufacturing.

 

Both new kits fully comply with serum-free, xeno-free and low-endotoxin standards. The comprehensive in-house QC system delivers consistent, controllable and traceable data to support IND and BLA filings for cell therapy and exosome therapeutics. Bio-Engine also provides customized liquid medium in bottles and bag formats to satisfy diverse production scales from early-stage R&D to commercial manufacturing.

 

About Bio-Engine

BioEngine Sci-Tech Co, Ltd.  specializes in independent R&D and large-scale manufacturing of high-performance serum-free cell culture media. The company's cell culture technology roots trace back to 1986, making it one of China's earliest research teams dedicated to cell culture technology. Its product portfolio covers antibody production, vaccine development and CGT (Cell and Gene Therapy), supporting over 150 clinical programs with more than 400 global clients.

Order Information

 

Product Kits

Product Name	Catalog No.	Specification	Remarks
Omni-Expansion MSC Culture Kit (Phenol Red-Free)	--	--	--
Omni-Expansion MSC Serum-Free Medium	TP0117101	500 mL/bottle	Custom liquid bag packaging available
Omni-Expansion Supplement	TP0202801	15 mL/bottle	--
Exo MSC CD Exosome Expression Kit (Phenol Red-Free)	--	--	Catalog No. TP0301101
Exo MSC CD Basal Medium	TP0112201	1 L/bottle	--
Exo MSC CD Supplement	TP0202001	1 mL/vial	--

For alternative specifications and customized formulation services, please contact our sales team.

 

Media Inquiries

BioEngine Sci-Tech Co, Ltd
Tel: +86 21-68582660
Email: marketing@bio-engine.com.cn
Website: www.bio-engine.com.cn